SCHEMBL31653824

SCHEMBL31653824

C=CC(=O)Nc1ccccc1-c1c(CC)nc2n(CC(=O)Nc3ccc(F)cc3)c3ccccc3n2c1=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ POLB P06746 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ RORC P51449 4/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ MAPT P10636 7/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ TP53 P04637 2/20 0.38
▸ GAA P10253 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ RECQL P46063 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31653724 0.94 POLB (0.44) KDM4EPOLBTDP1RORCALDH1A1
SCHEMBL31653845 0.93 POLB (0.51) SMN1; SMN2POLBTDP1RORCALDH1A1
SCHEMBL31653762 0.92 KDM4E (0.42) KDM4ESMN1; SMN2POLBTDP1RORC
SCHEMBL31653782 0.92 MAPT (0.42) KDM4ESMN1; SMN2POLBTDP1RORC
SCHEMBL31653877 0.92 RORC (0.45) KDM4ESMN1; SMN2POLBTDP1RORC
SCHEMBL31677853 0.91 KDM4E (0.42) KDM4ESMN1; SMN2POLBTDP1RORC
SCHEMBL31653789 0.89 POLB (0.41) POLBMAPTTP53GAALMNA
SCHEMBL31653872 0.89 SMN1; SMN2 (0.39) KDM4ESMN1; SMN2POLBTDP1ALDH1A1
SCHEMBL31653661 0.89 THRB (0.39) KDM4ESMN1; SMN2POLBRORCALDH1A1
SCHEMBL31653697 0.86 MAPT (0.53) SMN1; SMN2POLBRORCHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215006-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-07-03 — — US claimed
US-20250215006-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN INCYTE CORPORATION (US) 2025-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215006-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF WRN WRN, BLM, RECQL KDM4E 3756/4885SMN1; SMN2 1990/4885POLB 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback